Khot Shareholders Approve all Resolutions including Change of Name to "Blockchain Holdings Ltd." at its Annual General and Special Meeting
TORTOLA, British Virgin Islands, April 18, 2018 (GLOBE NEWSWIRE) -- Khot Infrastructure Holdings, Ltd. (the "Company") (CSE:KOT) is delighted to announce at the Company's annual general and special meeting of shareholders held on April 9, 2018 (the "Meeting"), all agenda items and proposals put forward by the Board of Directors, as further described in the Company's information circular dated March 9, 2018, were approved, including the following:
- Proposed Change of Business from transportation infrastructure in Mongolia to developing proprietary indexes and ancillary data products for emerging blockchain and digital currency markets.
- Amendment to the Company's articles of incorporation to change the name of the Company to "Blockchain Holdings Ltd."
- Setting the number of directors of the Company until the next annual general meeting at five.
- Elected to the board of directors are: James Passin, Executive Chairman, Don Padgett, Jeremy Gardner, Wayne Lloyd and Gregory Kallinikos.
- Re-appointment of Dale Matheson Carr-Hilton Labonte LLP ("DMCL LLP") as auditors of the Company for the ensuing financial year and the Director's right to fix the remuneration to be paid to DCML LLP.
- New rolling 10% Stock Option Plan.
- Sale of its Mongolian subsidiary, Ashid Munkhiin Zam LLC.
- Amendment to the articles of the Company to consolidate the outstanding common shares of the Company (the "Consolidation") on the basis of one (1) post-Consolidated common share for every ten (10) pre-Consolidated common shares. Registered shareholders of the Company received a letter of transmittal containing instructions on how to obtain new share certificates of the Company by mail. The letter of transmittal is posted on SEDAR under the Company's profile at www.sedar.com and is subject to final acceptance from the Canadian Securities Exchange.
Kenneth Farrell resigned from the Company's Board of Directors effective March 15, 2018. Erin Chutter and Orgilmaa Siizkhuu did not stand for re-election at the Meeting. The Company thanks Mr. Farrell, Ms. Chutter and Ms. Siizkhuu for their contribution during the time of their directorships and wishes them well in their future endeavours.
The Company is also pleased to announce that further to its press release of March 26, 2018, it has completed its non-brokered private placement (the "Private Placement") of subscription receipts (each, a "Receipt") for gross proceeds of $500,000 at a price of $0.10 per Receipt (assuming the completion of the Consolidation). The proceeds of the Private Placement will be held in escrow pending the completion of the transactions approved at the Meeting, whereupon, each Receipt will automatically convert into one common share of the Company, as constituted following completion of the Consolidation.
The Private Placement is subject to regulatory approval, and any securities to be issued pursuant to the Private Placement are subject to a four-month and one day hold period under applicable Canadian securities law.
The proceeds of the Private Placement will be used for the development of proprietary indexes and ancillary data products for emerging blockchain and digital currency markets, and for working capital and general corporate purposes.
The Company confirms that it has reached agreement with its lenders to repay CAD$628,304.68 in debt by the issuance of 6,283,047 common shares of the Company at a price of $0.10 per share (assuming the completion of the Consolidation).
On completion of the Consolidation, Private Placement and debt conversion, the outstanding share capital of the Company will be approximately 17,813,282 common shares (post Consolidated) on a non-diluted basis.
James Passin, Chairman, stated, "It is an honor to welcome legendary cryptocurrency pioneer, Jeremy Gardner, and accomplished technology entrepreneur and professional investment manager, Wayne Lloyd, to the Board of Directors. With the closing of the debt settlements and private placement, the Company is now positioned to launch its new cryptocurrency/blockchain proprietary indexing business. We are excited to announce additional new future business initiatives under the Company's strengthened board and executive team. Our strategic objective is to generate returns for our shareholders by carving out a role for the Company in the exponentially expanding cryptocurrency and blockchain ecosystem."
For further information, please contact:
Alan Tam, CFO
+1 604 377-7575
+1 604 220 2000
This press release was prepared by management of the Company, which takes full responsibility for its contents. The Canadian Securities Exchange or its regulators have, in no way passed upon the merits of the proposed transaction and has neither approved or disapproved the contents of this press release.
Disclaimer for Forward-Looking Information
Statements containing forward-looking information express, as at the date of this news release, the Company's plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and are believed to be reasonable based on information currently available to the Company. Forward-looking statements and information are based on assumptions that financing and personnel will be available when required and on reasonable terms, and all necessary regulatory approvals and shareholder approval will be obtained, none of which are assured and are subject to a number of other risks and uncertainties.
There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Khot Infrastructure Holdings, Ltd. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45 | Pressmeddelande
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH
Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30 | Pressmeddelande
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional
Elemica Reports Double Digit Network Growth and Announces New Product Innovations in First Quarter 201824.5.2018 18:18 | Pressmeddelande
Helping Process Manufacturers Undergo Digital Transformation Leads to Introduction of New Transformative Solutions WAYNE, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces the company's first quarter results of 2018 highlighting substantial network growth and new product innovations. The Elemica Digital Supply Network had significant network expansion in the first quarter with traffic growing 10 percent year-over-year in Q1. Shipment traffic grew substantially based on new product expansions of Elemica Trace. "Elemica's growth can be attributed to our clients needing our expertise and technology to undergo a Digital Transformation that connects, automates, anticipates and transforms their enterprise for their business growth initiatives," said John Blyzinskyj, CEO of Elemica. "Our digital supply network enables businesses to grow their top and bottom lines, mitigate risk and improve customer satisfaction ac
Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16 | Pressmeddelande
London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h
SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00 | Pressmeddelande
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00 | Pressmeddelande
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum